Relationship of cyclosporin and sirolimus blood concentrations regarding the incidence and severity of hyperlipidemia after kidney transplantation

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 1, 2006, Pages 19-30

  Spinelli, G A ^a   Felipe, C R ^a   Machado, P G ^a   Garcia, R ^a   Casarini, D E ^a   Moreira, S R ^a   Park, S I ^a   Tedesco Silva, H ^a   Medina Pestana, J O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cholesterol; Cyclosporin A; Hyperlipidemia; Kidney transplantation; Sirolimus; Triglyceride

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CERIVASTATIN; CHOLESTEROL; CYCLOSPORIN A; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PRAVASTATIN; PREDNISONE; RAPAMYCIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 30744443233     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000100003     Document Type: Article

References (29)

1. Donald EH (2000). Hyperlipidemia in renal transplant recipients. Graft 3: 177-184.
2. Wissing KM, Daniel A, Nilufer B et al. (2000). Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation, 70: 464-472.
3. Gokal R, Mann JI, Moore RA at al. (1979). Hyperlipidemia following renal transplantation. Quarterly Journal of Medicine, 48: 507-517.
4. Kasiske BL & Umen AJ (1987). Persistent hyperlipidemia in renal transplant recipients. Medicine, 66: 309-316.
5. Vathsala A, Weinberg RB, Schoenberg L at al. (1989). Lipid abnormalities in cyclosporin-prednisone-treated renal transplant recipients. Transplantation, 48: 37-43.
6. Kahan BD, for the Rapamune US Study Group (2000). Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet, 356: 194-202.
7. MacDonald AS, for the Rapamune Global Study Group (2001). A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporin regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation, 71: 271-280.
8. Shih-Chieh JC & Kahan BD (2003). Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporin-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation, 76: 375-382.
9. Kirk JK & Dupuis RE (1995). Approaches to the treatment of hyperlipidemia in the solid-organ transplant recipient. Annals of Pharmacotherapy, 29: 879-891.
10. Chan MK, Varghese Z, Ppersaud JW et al. (1981). The role of multiple pharmacotherapy in the pathogenesis of hyperlipidemia after renal transplantation. Clinical Nephrology, 15: 309-313.
11. Derfler K, Hayde M & Heinz G (1991). Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin. Kidney Internatlonal, 40: 720-727.
12. Apanay DC, Neylan JF, Ragab MS et al. (1994). Cyclosporin increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation, 58: 663-669.
13. Morrisett JD, Chada AF, Hoogeveen R et al. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels and fatty acid metabolism in renal transplant patients. Journal of Lipid Research, 43: 1170-1180.
14. Kahan BD & Kramer WG (2001). Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clinical Pharmacology and Therapeutics, 70: 74-81.
15. Kahan BD, Knight R, Schoenberg L et al. (2003). Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. Transplantatfon Proceedings, 35: 25S-34S.
16. Kelly P & Kahan BD (2002). Review: metabolism of immunosupressant drugs. Current Drug Metabolism, 3: 275-287.
17. Di Marco GS, Andrade MCC, Felipe CR et al. (2003). Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection. Therapeutic Drug Monitoring, 25: 558-564.
18. Christians U, Jacobsen W & Floren LC (1998). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacology Therapeutics, 80: 1-34.
19. Johnson RWG (2002). Sirolimus (Rapamune) in renal transplantation. Current Opinion in Nephrology and Hypertension, 11: 603-607.
20. Cosio FG, Todd EP, Ronald PP et al. (2002). Patient survival after renal transplantation III: The effects of statin. American Journal of Kidney Diseases, 40: 638-643.
21. Kahan BD, Napoli KL, Kelly PA et al. (2000). Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clinical Transplantation, 14: 97-109.
22. Kreis H, Cisterne JM, Land W et al. (2000). Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation, 69: 1252-1260.
23. Flechner SM, Goldfarb D, Modlin C et al. (2002). Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporin. Transplantation, 74: 1070-1076.
24. Johnson RWG, Kreis H, Oberbauer R et al. (2001). Sirolimus allows early cyclosporin, withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation, 72: 777-786.
25. Velose A Timothy SL, Gloor JM et al. (2001). Cyclosporin elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of kidney Diseases, 38: S3-S10.
26. Huffman TA, Isabelle MS & John Jr CL (2002). Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Pharmacology, 99: 1047-1052.
27. Takano A, Usui I & Haruta T (2001). Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Molecular and Cellular Biology, 21: 5050-5062.
28. Tur MD, Garrigue V, Vela C et al. (2000). Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: Implications in transplantation-induced dyslipidemia. Transplantation Proceedings, 32: 2783-2784.
29. Ron CH, Ballantyne CM, Pownall HJ et al. (2001). Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation, 72: 1244-1250.